
Remi Meds Review
Best for: per-dose-tier compounded GLP-1 with named Strive Pharmacy partner
Remi Meds is a DTC compounded-GLP-1 telehealth platform offering per-dose-tier compounded semaglutide and tirzepatide-with-B12, plus NAD+, Sermorelin, and Glutathione add-ons. It names its pharmacy partner (Strive Pharmacy, Gilbert, AZ) and clinical network (Beluga Health), and surfaces full per-tier pricing rather than a floor-only "as low as." Semaglutide runs $249–$369/mo and tirzepatide $349–$639/mo. (Distinct from Remedy Meds.)
What the monthly price covers
Medication
Included
Provider visits
Not disclosed
Shipping
Not disclosed
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Remi Meds is a solid telehealth option with balanced features and pricing.
Remi Meds at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $249/mo
- Pricing model
- Scales with dose — higher doses cost more
- What's included
- Medication
- FDA status
- No FDA warning letter on record
How we scored Remi Meds
Each dimension is scored algorithmically from Remi Meds’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
4.6/10At $249/mo, Remi Meds runs about 47% above the $170 median for GLP-1 providers. Note the price scales with dose, so budget for higher tiers as you titrate.
Effectiveness25%
6.5/10Remi Meds offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
5.6/10Online intake and platform experience; 7 platform features disclosed.
Trust & Safety15%
6.4/10Core details confirmed by our editors; no FDA warning letters on file; dispenses through an accredited compounding pharmacy (last checked 2026-06-06).
Accessibility10%
4.5/10Remi Meds's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
4.3/10Remi Meds provides standard clinician follow-up; no extended coaching or community program is disclosed.
How we verified this Remi Meds review
Last checked 2026-06-06- Confirmed current pricing across 4 dose/plan tiers
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications Remi Meds offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Peptides Remi Meds offers
Beyond GLP-1s, Remi Meds also offers these peptides — tap any for our evidence-based guide.
Pricing
Ready to get started?
Plans and promotions change often — check Remi Meds's current pricing and active discounts before you decide.
What we like
- Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
- LegitScript verification badge on the homepage
- Publishes 503A FDCA compliance language on the tirzepatide page
- Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
- Operating corporate entity disclosed (T-C Health Co)
- Does not sell retatrutide — aligned with current FDA enforcement
- Clear non-affiliation disclaimer for Wegovy/Ozempic/Mounjaro trademarks
Watch-outs
- No named medical director, founder, or physician on any public page
- States served not listed — 'nationwide' claim with no per-state detail
- Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
- Year founded and corporate history are opaque
- Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure
- Mailing address (Leesburg FL) doesn't match the operating-entity state (California)
- HIPAA notice present but no third-party security attestation
Remi Meds: a transparent price list with a thin paper trail on the people behind it
Remi Meds is a direct-pay, compounded-only GLP-1 telehealth shop that does two things most of its competitors won't: it names the pharmacy that actually fills your prescription, and it publishes its full per-dose price ladder instead of teasing you with a single 'as low as' floor. That candor is genuinely useful when you're shopping. The catch is that the same site that's upfront about pricing stays quiet about who its medical leadership is — so this review is really about weighing one strong form of transparency against a notable gap in another. If you value seeing the real number for the exact dose you'll be on, Remi Meds earns a look. If you want a named medical director and a clear corporate history, you'll want to read the cautions below first.
How the pricing actually works: five tiers that climb with your dose
Remi Meds uses a scales-with-dose model, which is the honest way to price compounded GLP-1s and also the one that can surprise you later. You don't pay one flat rate — your monthly cost rises as your dose is titrated up. Compounded semaglutide starts at $249 a month at the 0.25 mg starting dose and steps up to the high-three-hundreds at the 2.4 mg maintenance dose. Compounded tirzepatide, which Remi Meds bundles with B12, opens in the mid-three-hundreds and climbs to the low-six-hundreds at the top maintenance tier.
The important takeaway: budget for where you'll END up, not where you start. The starting-dose price is real, but most people titrate upward over a few months, and the maintenance tiers are where you'll actually live. Even so, the entry semaglutide rate sits above the category median of $170 a month, so Remi Meds isn't competing on being the cheapest — it's competing on showing you the whole ladder before you commit. There's no published teaser or first-month promo rate here; the tiered list is the deal.
The medications and who fills them
This is compounded territory only — no brand-name Wegovy, Ozempic, Mounjaro or Zepbound, and Remi Meds is careful to post a non-affiliation disclaimer for those trademarks. You get compounded semaglutide and compounded tirzepatide-with-B12 as the core offerings, with NAD+, Sermorelin and Glutathione available as add-ons if you're after the broader wellness menu.
What sets Remi Meds apart is that it tells you the medication is filled by Strive Pharmacy in Gilbert, Arizona — a specific, lookup-able compounding pharmacy, not an anonymous 'licensed partner.' Most compounded-GLP-1 sellers won't give you that name. Pair that with the §503A FDCA compliance language on the tirzepatide page and a LegitScript badge on the homepage, and you have more of a verifiable supply chain than the average direct-pay compounder offers.
The retatrutide signal worth noticing
One small detail says a lot about how Remi Meds plays it: the site does not sell retatrutide, the experimental triple-agonist that the FDA moved against in September 2025. Plenty of compounding sellers kept pushing it anyway. A provider that quietly declines to stock a molecule regulators are actively warning about is showing the kind of restraint you want from a company handling prescription injectables. It's a green flag in an industry that has plenty of red ones.
What gives us pause
For all its pricing candor, Remi Meds is opaque about the things a YMYL review has to scrutinize. No medical director, founder, or physician is named anywhere on the public site. The states it serves aren't listed — it makes a blanket 'nationwide' claim with no per-state detail. And the corporate footprint is a little mismatched: the operating entity is T-C Health Co, organized in California, but the mailing address is in Leesburg, Florida, and a secondary 'Rekindle RX' email and a second phone number on the homepage hint at shared back-office infrastructure that isn't explained.
- No named clinician or leadership — you can't see who's overseeing your care or running the company.
- Clinical care runs through Beluga Health, a physician network a 2026 StatNews analysis tied to a large share of FDA-warned GLP-1 telehealth companies. Remi Meds itself has no FDA warning letter, but the network-level association is worth knowing.
- Direct-pay only — no insurance is accepted, and the refund policy is 'all sales final,' so there's no money-back cushion if it isn't a fit.
- Year founded and corporate history are unclear, which makes it hard to judge track record.
Trust and safety: a medium-confidence verdict
To be fair about the safety picture: Remi Meds clears several bars that matter. The site is real and reviewed end to end, the GLP-1 offerings are verified, the pharmacy is named, the LegitScript badge is present, the §503A language is posted, and there's no FDA warning letter against Remi Meds or T-C Health Co. One important note — don't confuse this company with Remedy Meds, a separate brand that did receive an FDA warning letter; Remi Meds is a different corporate entity with a clean letter record. Still, the missing medical leadership, the unenumerated state list, and the Beluga network association keep our confidence at MEDIUM rather than high. Our scoring methodology weighs disclosed oversight heavily, and that's exactly where Remi Meds leaves points on the table.
Who should choose Remi Meds — and who should skip it
Choose it if you're a confident self-pay shopper who wants to see the real per-dose price up front, values knowing the filling pharmacy by name, and prefers a seller that steers clear of the molecules regulators are chasing. Skip it if you need insurance billing, want a named physician or medical director you can vet, require a clear list of the states served before you'll enter payment details, or want any refund protection beyond 'all sales final.'
Bottom line
Remi Meds is a better-than-average compounded-GLP-1 platform on the dimensions it chooses to be transparent about — pricing, pharmacy, and regulatory restraint — and noticeably thin on the dimensions it doesn't, namely named medical oversight and corporate clarity. The honest price ladder and the Strive Pharmacy disclosure are real reasons to consider it over a floor-only competitor. Just go in clear-eyed: confirm the dose you'll ultimately need (and its price), accept that there's no insurance path or refund, and decide whether a platform with no named clinician meets your bar for a long-term medication you'll inject every week.
Worth pricing against Enhance MD ($212/month) and Direct Meds ($249/month) before you commit — both sit close to Remi Meds on cost and formulation.
Ready to start with Remi Meds?
Starting at $249/month. See current pricing and start your free consultation.
Remi Meds might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Alternatives to Remi Meds
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Remi Meds review:
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Ready to start with Remi Meds?
Starting at $249/month. See current pricing and start your free consultation.